Shelley B. Thunen Sells 10,000 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the transaction, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

RxSight Stock Performance

NASDAQ:RXST opened at $56.99 on Thursday. The stock’s fifty day moving average is $58.63 and its 200 day moving average is $52.26. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). The firm had revenue of $29.51 million for the quarter, compared to the consensus estimate of $27.56 million. RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The company’s revenue was up 68.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.42) EPS. As a group, equities analysts predict that RxSight, Inc. will post -0.77 earnings per share for the current year.

Institutional Trading of RxSight

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. grew its stake in shares of RxSight by 1.1% during the first quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock valued at $177,581,000 after buying an additional 38,540 shares during the last quarter. California State Teachers Retirement System boosted its holdings in RxSight by 6.8% during the 1st quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock valued at $1,395,000 after acquiring an additional 1,733 shares during the period. Caxton Associates LP bought a new position in RxSight in the 1st quarter valued at $1,208,000. Price T Rowe Associates Inc. MD grew its position in RxSight by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock valued at $3,143,000 after acquiring an additional 994 shares during the last quarter. Finally, Seven Eight Capital LP increased its stake in RxSight by 12.1% in the first quarter. Seven Eight Capital LP now owns 30,166 shares of the company’s stock worth $1,556,000 after purchasing an additional 3,248 shares during the period. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Stifel Nicolaus increased their price target on RxSight from $64.00 to $68.00 and gave the company a “buy” rating in a research note on Monday, May 6th. BTIG Research increased their target price on RxSight from $61.00 to $72.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Wells Fargo & Company boosted their price target on shares of RxSight from $61.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Oppenheimer upped their price target on shares of RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, May 7th. Finally, Needham & Company LLC lifted their price objective on shares of RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $60.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.